CO2018002575A2 - Composición de estabilidad mejorada de etanercept - Google Patents

Composición de estabilidad mejorada de etanercept

Info

Publication number
CO2018002575A2
CO2018002575A2 CONC2018/0002575A CO2018002575A CO2018002575A2 CO 2018002575 A2 CO2018002575 A2 CO 2018002575A2 CO 2018002575 A CO2018002575 A CO 2018002575A CO 2018002575 A2 CO2018002575 A2 CO 2018002575A2
Authority
CO
Colombia
Prior art keywords
etanercept
improved stability
stability composition
composition
sectors
Prior art date
Application number
CONC2018/0002575A
Other languages
English (en)
Inventor
Breña Romero De Terreros Francisco Kuri
Original Assignee
Landsteiner Scient S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57983405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018002575(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Landsteiner Scient S A De C V filed Critical Landsteiner Scient S A De C V
Publication of CO2018002575A2 publication Critical patent/CO2018002575A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una formulación líquida estable de Etanercept que reduce eficazmente la producción de subproductos de Etanercept, manteniendo de forma estable la eficacia farmacéutica del medicamento durante un almacenamiento a largo plazo. La composición líquida de la invención se proporciona en jeringas pre-llenadas listas para su aplicación inmediata a los sectores con necesidad de tratamiento con Etanercept.
CONC2018/0002575A 2015-08-13 2018-03-12 Composición de estabilidad mejorada de etanercept CO2018002575A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2015010517A MX2015010517A (es) 2015-08-13 2015-08-13 Composicion de estabilidad mejorada de etanercept.
PCT/MX2016/000082 WO2017026881A1 (es) 2015-08-13 2016-08-09 Composición de estabilidad mejorada de etanercept

Publications (1)

Publication Number Publication Date
CO2018002575A2 true CO2018002575A2 (es) 2018-06-12

Family

ID=57983405

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002575A CO2018002575A2 (es) 2015-08-13 2018-03-12 Composición de estabilidad mejorada de etanercept

Country Status (9)

Country Link
EP (1) EP3335729B1 (es)
JP (1) JP6852049B2 (es)
BR (1) BR112018002970A2 (es)
CO (1) CO2018002575A2 (es)
DK (1) DK3335729T3 (es)
ES (1) ES2956008T3 (es)
MX (1) MX2015010517A (es)
PT (1) PT3335729T (es)
WO (1) WO2017026881A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402716T1 (de) * 2002-02-27 2008-08-15 Immunex Corp Stabilisierte tnfr-fc formulierung mit arginin
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
TW201325606A (zh) * 2011-10-18 2013-07-01 Coherus Biosciences Inc 用氯化鈉穩定化之依那西普調配物
JP2015525762A (ja) * 2012-07-09 2015-09-07 コヒラス・バイオサイエンシズ・インコーポレイテッド エタネルセプトの安定な水性製剤
AU2013336279B2 (en) * 2012-10-26 2018-07-19 Lupin Limited Stable pharmaceutical composition of TNFR:Fc fusion protein

Also Published As

Publication number Publication date
BR112018002970A2 (pt) 2019-03-19
JP6852049B2 (ja) 2021-03-31
JP2018527343A (ja) 2018-09-20
MX2015010517A (es) 2017-02-13
EP3335729A1 (en) 2018-06-20
WO2017026881A1 (es) 2017-02-16
ES2956008T3 (es) 2023-12-11
EP3335729B1 (en) 2023-06-28
EP3335729A4 (en) 2019-06-05
PT3335729T (pt) 2023-09-26
DK3335729T3 (da) 2023-07-10

Similar Documents

Publication Publication Date Title
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP15007335A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
GB2556479B (en) Auto-injectors for administration of a medicament within a prefilled syringe
CR20160006A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CO7190242A2 (es) Moduladores del transporte nuclear y usos de los mismos
CL2016000117A1 (es) Autotaxina inhibidores comprende un anillo heteroaromático-bencilamina ciclo basico
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201590058A1 (ru) Аналоги глюкагона
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018000282A1 (es) Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol
EA201500242A1 (ru) Медицинский аппликатор
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EP3305347A4 (en) LIQUID INFUSION DEVICE FOR MEDICINE ADMINISTRATION TO A PATIENT
MD4763C1 (ro) Compoziţie farmaceutică
CL2015000052A1 (es) Composición farmacéutica con fluidez mejorada, que comprende 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, lactulosa, peg-6000 y pvp; comprimido o capsula que la comprende y metodo para su producción.
CO2018002575A2 (es) Composición de estabilidad mejorada de etanercept
ECSP16070463A (es) Filtros para equipos de infusión campo de la invención
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
PE20170130A1 (es) (s) - pirlindol y sus sales farmaceuticamente aceptables para uso en medicina